Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK's mRNA-CR-04 Vaccine in Healthy Adults
NCT05972993Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2023
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mRNA-CR-04 in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any Solicited Administration Site Events, Number of Participants With Any Solicited Systemic Events and 5 more. Started Aug 2023; status: completed.
02
Drugs
mRNA-CR-04
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05972993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972993.